GlassScriptPhysician profile
George L Barrett
NPI 1659549590
$36,791.43
in general payments reported to CMS, 2019-2025
25 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $3,331 · 2021: $13K · 2022: $5,740 · 2023: $2,651 · 2024: $8,151 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $2,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,605.00 |
| Food and Beverage | $2,915.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $17,567.07 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $9,610.07 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $4,708.71 | 2021-2023 | |
| Romark Laboratories, Lc | $1,273.05 | 2019-2020 | |
| Abbvie INC. | $958.40 | 2020-2025 | Linzess, Creon, Viberzi |
| Janssen Biotech, INC. | $399.01 | 2022-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $386.59 | 2021-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.49 | 2020-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $233.14 | 2019-2023 | Sucraid |
| Neurocrine Biosciences, INC. | $157.63 | 2022-2023 | Ingrezza |
| Madrigal Pharmaceuticals | $155.47 | 2025 | Rezdiffra |
| Boston Scientific Corporation | $141.78 | 2023 | |
| Intercept Pharmaceuticals, INC. | $133.22 | 2021-2024 | Ocaliva |
| Genzyme Corporation | $129.98 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $120.16 | 2020-2024 | Dificid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $105.03 | 2023-2024 | Dupixent |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Aimmune Therapeutics, INC. | $54.69 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $49.54 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $45.11 | 2020-2023 | Linzess |
| Organon LLC | $41.99 | 2022-2024 | |
| Celltrion USA INC. | $23.31 | 2025 | Vegzelma |
| Celgene Corporation | $21.77 | 2024 | Zeposia |
| Alfasigma USA, INC. | $21.44 | 2020 | |
| Exact Sciences Corporation | $19.78 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Barrett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.